CASP3 and neoplasm: Accordingly, tumors that were segregated as responders to cetuximab (9/40, ~22%) showed a significant reduction in viability/tumor content or proliferation and a concomitant increase in activated caspase-3 post-treatment, compared with the vehicle control (Supplementary Fig. S1A–D).